About Us


Page 3«..2345..10..»

Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525

Posted: August 29, 2021 at 1:49 am

Sydney, Aug. 27, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 27 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce the grant of patent no. ZL201580013695.X entitled “Antibody molecules to LAG-3 and uses thereof” by the Chinese Patent Office.

Original post:
Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525

Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of…

Posted: at 1:49 am

LAVAL, Québec, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti”) (NASDAQ: ACST–TSX-V: ACST), announced today the completion of its previously disclosed acquisition of Grace Therapeutics, Inc. (“Grace”) via merger. The successful completion of the merger positions Acasti to build a premier, late-stage specialty pharma company focused on rare diseases. Based on management’s current forecasts, Acasti expects to have enough cash on its balance sheet following the merger to provide at least two years of operating runway. The combined companies will be led by Jan D’Alvise as President and Chief Executive Officer, under the oversight of Acasti’s newly elected Board of Directors, comprised of four re-elected directors of Acasti and two Grace nominees newly elected as directors (with a third Grace nominee expected to be nominated prior to the next annual meeting of shareholders). All Grace employees will transition to Acasti and they will continue to maintain a research and development laboratory and commercial presence in North Brunswick, New Jersey.

See the rest here:
Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of...

In H1 2021 Olainfarm Group continues stable growth

Posted: at 1:49 am

The compiled financial indicators for the first six months of this year confirm the growth of Olainfarm Group. The financial performance measures of both Olainfarm and its subsidiaries have grown steadily, compared to the same period last year, which means that we are heading in the right direction. The pandemic has not affected our operations significantly either. Russia is still our biggest market, with a significant increase of medicine sales. Ukraine now is in the second place, while the usual second-largest market, Belarus, has dropped to the third position. Overall, financially we are on track with the budget and we are performing well,” J?nis Buks, Chairman of the Management Board of JSC Olainfarm.

Originally posted here:
In H1 2021 Olainfarm Group continues stable growth

Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer’s Patients

Posted: at 1:49 am

AUSTIN, Texas, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today released a statement regarding plasma p-tau analysis from a previously disclosed randomized, controlled Phase 2b clinical study in patients with Alzheimer’s disease. For this study, Cassava Sciences contracted with Quanterix Corp., a highly regarded, independent laboratory, to perform sample testing on blinded samples.

Continue reading here:
Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer’s Patients

Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer

Posted: at 1:49 am

Basel, 27 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumours express PD-L1, as determined by a US Food and Drug Administration (FDA)-approved test. Roche made this decision following consultation with the US FDA, based on the agency’s assessment of the current mTNBC treatment landscape and in accordance with the requirements of the accelerated approval programme. This decision only impacts the mTNBC indication in the US. It does not affect other approved indications for Tecentriq in the US and outside the US, including mTNBC. This is not related to any changes in either the efficacy or safety associated with Tecentriq.

View post:
Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer

BioAegis Therapeutics Announces Publication of a Compassionate Use Case Study of a Critical COVID-19 Patient

Posted: at 1:49 am

Gelsolin immunomodulator treatment associated with patient’s rapid recovery.

BioAegis Therapeutics Announces Publication of a Compassionate Use Case Study of a Critical COVID-19 Patient

Bone Therapeutics strengthens its financial structure with the implementation of its financing agreement with the European Investment Bank and the…

Posted: at 1:49 am


Originally posted here:
Bone Therapeutics strengthens its financial structure with the implementation of its financing agreement with the European Investment Bank and the...

Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action

Posted: at 1:49 am

WAYNE, Pa., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that a settlement hearing (the “Settlement Hearing”) will be held on November 30, 2021 at 11:00 a.m. ET, before the Honorable Lewis J. Liman at the U.S. District Court for the Southern District of New York, 500 Pearl Street, New York, NY 10007 (the “Court”) in the matter of In re Aclaris Therapeutics, Inc. Derivative Litigation, Lead Case No. 1:19-cv-10641-LJL (the “Consolidated Derivative Action”).

More here:
Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action

Biomerica Reports Fiscal 2021 Year End Results

Posted: at 1:49 am

IRVINE, Calif., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products, today reported its fiscal 2021 financial results. During the year the Company made significant progress in its business by increasing its number of allowed patents covering its InFoods® diagnostic guided therapy technology, signing a distribution agreement for its H. Pylori product which is expected to be filed with FDA in October, 2021, and has entered into negotiations with major retailers/distributors for sales of its EZ Detect colorectal disease test.

See the original post here:
Biomerica Reports Fiscal 2021 Year End Results

ImmixBio Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate Combination of IMX-110 and Tislelizumab in Solid Tumors | Small…

Posted: at 1:49 am

DetailsCategory: Small MoleculesPublished on Saturday, 28 August 2021 18:14Hits: 328

Novel Approach Combining ImmixBio Tissue Specific Therapeutics (TSTx) with Immunotherapies Could Expand the Population Of Cancer Patients Experiencing Extended Remissions

LOS ANGELES, CA, USA I August 27, 2021 I Immix Biopharma, Inc. ("ImmixBio") today announced a clinical trial and supply agreement with BeiGene, Ltd. to evaluate the safety, tolerability and efficacy of combining IMX-110, a Tissue Specific Therapeutic with TME Normalization Technology, with BeiGene's anti-PD-1 antibody tislelizumab, for the treatment of various solid tumors, in the U.S. and internationally.

Under the terms of the agreement, ImmixBio will evaluate the combination of IMX-110 with tislelizumab in a Phase 1/2a trial in patients with advanced solid tumors.


"ImmixBio is proud to showcase our Tissue Specific Therapeutics (TSTx) platform to the world. Promising data from our ongoing IMX-110 clinical trial, from pre-clinical studies in a genetic mouse model of pancreatic cancer showing IMX-110 turning "cold" tumors "hot," and IMX-110 in combination with murine anti-PD-1 demonstrating extended survival in a genetic mouse model of pancreatic cancer versus multi-drug combinations in the literature, have demonstrated substantial rationale to combine IMX-110 and tislelizumab," said Ilya Rachman, MD, PhD ImmixBio CEO. "We have high hopes that IMX-110 in combination with tislelizumab could expand the population of cancer patients experiencing extended remissions."

About IMX-110

IMX-110 is a Tissue-Specific Therapeutic built on ImmixBio's TME Normalization Technology encapsulating a poly-kinase inhibitor and apoptosis inducer delivered deep into the tumor micro-environment, or TME. ImmixBio's TME Normalization Technology enables IMX-110 to circulate in the bloodstream, then exit through porous tumor blood vessels, and accumulate in the TME. IMX-110 then simultaneously attacks all 3 components of the TME (cancer associated fibroblasts, or CAFs; tumor-associated macrophages/immune cells, or TAMs, and cancer itself), severing the critical lifelines between the tumor and its metabolic and structural support. IMX-110's TME Normalization Technology causes tumor apoptosis, a non-inflammatory tumor-cell death (vs. necroptosis, which results in repeat reignition of the inflammatory cascade leading to tumor progression).

IMX-110 is currently being evaluated in a phase 1b/2a open-label, dose-escalation/dose-expansion safety, tolerability and pharmacokinetic study in patients with advanced solid tumors in the United States and Australia.

About Tislelizumab

Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcR on macrophages. In pre-clinical studies, binding to FcR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is being developed internationally as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.

The China National Medical Products Administration (NMPA) has granted tislelizumab market authorization in four indications, including full approval for first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy. Tislelizumab is not approved for use outside of China.

In January 2021, BeiGene and Novartis entered into a collaboration and license agreement granting Novartis rights to develop, manufacture, and commercialize tislelizumab in North America, Europe, and Japan.

About ImmixBio

ImmixBio is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx) in oncology and inflammation. Our lead asset, IMX-110, is currently in phase 1b/2a clinical trials for solid tumors in the United States and Australia. Our proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times the rate of conventional medicines. Our TME Normalization Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. We have uncovered fundamental biological systems that link oncology and inflammation. In addition to oncology, our pipeline includes Tissue-Specific Biologic candidates to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Learn more at http://www.immixbio.com

SOURCE: ImmixBio

Read more from the original source:
ImmixBio Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate Combination of IMX-110 and Tislelizumab in Solid Tumors | Small...

Laekna Therapeutics Receives IND Approvals in China and US for Phase Ib/III Global Multi-center Clinical Study of Afuresertib in combination with…

Posted: at 1:49 am

SHANGHAI and WAREN, New Jersey, Aug. 26, 2021 /PRNewswire/ -- Laekna Therapeutics announced today that the Center for Drug Evaluation (CDE), the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application of its Category 1 new drug candidate afuresertib (LAE002) in combination with anti-estrogen receptor drug fulvestrant in the Phase Ib/III clinical trial of patients with locally advanced or metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

This global multi-center clinical trial will be initiated simultaneously in the United States and China a month earlier than previously planned. The Phase III global registrational study will be started soon after afuresertib plus fulvestrant demonstrates proof of concept results in tolerability and anti-tumor efficacy in patients enrolled in the Phase Ib study.

Clinical trials of afuresertib cover four different cancers

Afuresertib (LAE002) is a clinically proven, with a first-in-class potential, highly potent small-molecule pan-AKT inhibitor. Currently, afuresertib is being studied in global clinical studies in four different cancers including ovarian cancer, prostate cancer, triple-negative breast cancer, and HR+/HER2- breast cancer. In the four ongoing clinical trials, afuresertib is explored in combination with chemotherapy, anti-androgen therapy, anti-PD-L1 monoclonal antibody, and anti-estrogen therapy, respectively.

Aiming to be a first-in-class AKT inhibitor

"The IND approval came one month earlier than expected, demonstrating the NMPA's prioritization and support for the clinical development of new treatment options for drug resistant breast cancer patients. It also showcases effective collaboration between our teams in the US and China," said Dr. Chris Lu, Chairman and Chief Executive Officer of Laekna Therapeutics. "We continue to be a tier-1 player globally in the development of AKT kinase inhibitors. We are accelerating multiple clinical trials to potentially make afuresertib a potential first-in-class therapy."

Striving to address drug resistance in patients with HR+/HER2- breast cancer

Breast cancer is the most common cancer among women worldwide. About 62% and 68% of all breast cancer patients in China and the US are HR+/HER2- respectively. Current treatment are available in the form of first- and second-line endocrine/anti-estrogen therapies and/or in combination of CDK4/6 inhibitors, or chemotherapy, however, the patients often develop drug resistance after a period of time.

"The HR+/HER2- subtype accounts for the largest subgroup of breast cancer. One of the urgent unmet medical needs is to provide a new therapy after patients develop resistance to prior standard of care treatments. It will also help significantly improve the clinical outcomes and quality of life for patients with breast cancer," said Dr. Yue Yong, Chief Medical Officer of Laekna Therapeutics. "Combination therapies based on afuresertib are being explored in clinical trials in patients with various types of drug-resistant cancers, and results showed preliminary anti-tumor efficacy and manageable safety profiles, particularly in ovarian and breast cancers. We expect these new treatment options will benefit patients and provide doctors with better choices in treating patients with drug-resistant tumors."

About AfuresertibLAE002

Afuresertib (LAE002) is a differentiated oral, small molecule pan-AKT kinase inhibitor that has been investigated in over 10 Phase 1/2 clinical trials, including ovarian cancer, gastric cancer, multiple myeloma, and melanoma. These studies have demonstrated that afuresertib has strong anti-cancer activities and a tolerable safety profile. The global randomized, open-label, multi-center Phase 2 PROFECTA-II clinical trial of afuresertib is the world's first registration-directed clinical study of a pan-AKT kinase inhibitor to treat platinum-resistant ovarian cancer.

In recent years, AKT (a serine/threonine-protein kinase) has emerged as an important mechanism in oncology, as it plays an important role in regulating various cell functions such as metabolism, survival, proliferation, tissue invasion, and chemotherapy resistance. PTEN deletion and AKT/PIK3CA alteration may lead to excessive activation of the AKT signaling pathways, which is one of the key drivers for cancer growth. The increased activation of the AKT signaling pathway is particularly common in recurrent ovarian cancer, breast cancer, and prostate cancer.

About Laekna Therapeutics

Founded in December 2016, Laekna Therapeutics is an emerging innovative pharma company based in China's "Zhangjiang Pharma Valley" and New Jersey in the US, focusing on developing new ground-breaking innovative therapies to treat cancer and liver diseases.

Laekna Therapeutics has adopted a two-pronged strategy in new drug development. On one hand, it continues to enrich its portfolio by introducing global new drugs with the clinical Proof of Concept. The company has obtained the global exclusive rights of four new drug candidates from Novartis. On the other hand, the company's self-developed innovative drugs will soon enter clinical development stage.

Laekna has set up a team of top global pharmaceutical talent. Its leadership team members each have over 20 years of experience in new drug development in China and the US, with an exceptional track record in R&D, new drug approvals and commercialization. Laekna is committed to a science-based, innovation-driven approach to create an international leading clinical research and development platform for the development of first-in-class and best-in-class innovative drugs.

The detail Laekna Therapeutics information can be found from the website: http://www.laeknatp.com

Contact Laekna TherapeuticsLeah Liu CFO[emailprotected]

Media Cleo Zhang 86-18516226288[emailprotected]

Corporate and Business DevelopmentGuy Rosenthal (US)[emailprotected]

SOURCE Laekna Therapeutics

Read more here:
Laekna Therapeutics Receives IND Approvals in China and US for Phase Ib/III Global Multi-center Clinical Study of Afuresertib in combination with...

Scientific Workforce Diversity and Health Disparities Research Programs – National Institute on Aging

Posted: at 1:49 am

With the goal of advancing the most innovative scientific ideas from investigators of all ethnic, racial, and cultural backgrounds, NIA works to diversify the aging research workforce, both within our institute and through the grantees we support. Additionally, we are committed to eliminating health disparities in research through a variety of ways, including novel recruitment initiatives to incorporate diverse participants in our clinical studies and trials.

NIA further seeks to understand the environmental, sociocultural, behavioral, and biological drivers of health inequities and disparities related to aging and diseases such as Alzheimers and related dementias. We support research to develop strategies for the improvement of health among midlife and older adults in underrepresented groups who experience health inequities or disparities. These priorities are outlined in NIAs strategic directions for health disparities research and reflected within NIAs Health Disparities Research Framework.

NIA leads initiatives, co-funds programs, and participates in NIH-wide efforts to improve research workforce diversity by increasing the number of trained researchers from underrepresented groups who can become leaders in aging research. Learn more about NIAs training opportunities for special populations.

NIAs Office of Special Populations (OSP) serves to support and strengthen the institutes work to understand and address health disparities in older adults.

The annual NIA Directors Regional Meeting provides an opportunity for scientists who might be less aware of NIAs funding opportunities in aging research, and/or are working at universities that may not have received significant NIH funding in the past, to interact with NIA leadership. Led by OSP, agendas feature types of awards available to researchers and trainees new to aging research or interested in health disparities research, as well as to those who are underrepresented in aging research. NIAs goals are to provide information on existing opportunities for research and training; provide hands-on technical assistance in grant writing; solicit advice on the design of new research opportunities; and discuss strategies for recruiting underrepresented students and investigators to aging research.

For decades, NIAs National Advisory Council on Aging (NACA) has convened the Task Force on Minority Aging Research as part of its meetings three times each year. Managed by OSP and the Minority Working Group, this task force was created to advise NACA on initiatives to increase the representation of minorities in aging research. It provides a quarterly summary of NIAs diversity programs and initiatives, including updates on meetings and conferences, diversity and health disparities research, and training programs and initiatives. NIA often invites renown health disparities in aging researchers to present at NACA.

The Butler-Williams Scholars Program, formerly known as the Summer Institute on Aging, provides unique opportunities for junior faculty and researchers new to the field to gain insight about aging research. The prestigious annual summer program builds upon a rich history of NIAs work to highlight different perspectives in aging research through dynamic presentations and small group discussions. NIA encourages researchers who are interested in health disparities research related to aging, and those who are underrepresented in aging research, to apply.

The NIA MSTEM Advancing Diversity in Aging Research through Undergraduate Education (ADAR) program is designed to enhance diversity in undergraduate science education. Through ADAR, NIA has provided more than 300 college students with coursework, lab instruction, and mentoring in aging related research. Learn more about the ADAR program and read profiles of students who have participated.

NIA's Diversity and Re-entry Supplement programs support the development of eligible trainee-candidates who seek independent careers in aging and geriatrics research and meet our goal to enhance workforce diversity. Supplemental awards provide funds to support a mentor-directed opportunity for a trainee-candidate to develop the critical thinking skills, scientific technical expertise, and professional acumen essential for career advancement in the biomedical, behavioral, clinical, or social sciences. Learn more about NIAs training opportunities for special populations and supplement programs.

NIA is committed to training researchers for lifetime careers in the biomedical and behavioral sciences. Through its Intramural Research Program (IRP), NIA offers multiple training opportunities in both laboratory and clinical medicine, along with a wealth of valuable resources.

The Diversity in Aging Research Pipeline Program (DARPP) is designed to develop and expose underrepresented and socioeconomically disadvantaged students to aging research. High school, college, graduate, medical, and postdoctoral students receive training from NIA IRP scientists in a highly mentored, structured environment. Students receive long-term support and follow-through during their experience with NIA and beyond.

NIAs Summer Trainee in Aging Research (STAR) Program offers unique internship opportunities for underrepresented and socioeconomically disadvantaged high school, college, graduate, and medical students. Based in Baltimore, internships last from eight to 10 weeks during the summer, and students get hands-on experience in scientific research settings and attend weekly seminars presented by NIA scientists. At the conclusion of the summer program, students present the data developed from their research projects at the NIA Summer Student Poster Day. Program participants receive a stipend to participate.

Many complex and interconnected factors can affect older adults health and quality of life. To develop and implement effective interventions to address health disparities among various populations, NIA supports and conducts research to:

Researchers from underrepresented groups or those interested in health disparities aging research can contact program officers for specific areas of interest, and learn how to find NIA funding opportunities, apply for grants and funding, and how the NIA peer review process works. Also see a full list of NIA-wide active funding opportunities, NIA-wide Alzheimers Disease and Alzheimers disease and related dementias (AD/ADRD)funding opportunities, and Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding opportunities.

The NIA Health Disparities Research Framework, overseen by OSP, outlines four key levels of analysis related to disparities research environmental, sociocultural, behavioral, and biological with priority focus areas in each category. Using the framework as a guide, NIA has awarded more than $250 million in research awards since 2015 to explore and address these determinants of health disparities related to aging.

The National Plan to Address Alzheimers Disease provides a framework for reaching our nations goal of effectively preventing and treating Alzheimers disease and related dementias by 2025. To this end, NIA led the development of implementation research milestones, which include research on health disparities in Alzheimers and related dementias and recruitment and participation of diverse participants clinical studies.

Through its Resource Centers for Minority Aging Research (RCMAR), since 1997, NIA has been mentoring promising scientists from underrepresented groups and playing a critical role in training the next generation of diverse researchers. Located at universities across the United States, the centers focus on health disparities and minority aging issues as a major part of their research education programs. In 2018, the RCMAR program was expanded to support additional centers focused on Alzheimers disease and related dementias research.

NIAs Intramural Research Program (IRP) scientists conduct a broad range of multidisciplinary, investigator-initiated research, including studies on health conditions and aging in diverse populations. Goals include investigating the biology of health disparities in the context of aging and disentangling the interaction between socioeconomic status and race in the development of age-associated health disparities. Other goals include mentoring the next generation of leaders in the epidemiology of aging, health disparities, and behavior.

Through the Healthy Aging in Neighborhoods of Diversity across the Life Span Study (HANDLS), NIA seeks to understand and address health disparities associated with race and socio-economic status in several Baltimore neighborhoods. Visit the Health Disparities Research Section to learn more.

One of the biggest hurdles in advancing Alzheimers and related dementias and other aging research is recruitment and retention of clinical study and trial participants, particularly those from underrepresented populations. It is important for clinical studies and trials to have participants of different ages, sexes, races, and ethnicities. When research involves a group of people who are similar, the findings may not be relevant to broader groups of individuals. When clinical trials include diverse participants, the study results may have a much wider applicability. NIA seeks to engage a more diverse range of older adults for the many clinical trials and studies it conducts and supports, including prevention and intervention trials on Alzheimers and related dementias.

As part of the National Plan to Address Alzheimers Disease, NIA intensified efforts to outline practical, proactive approaches to help researchers recruit and retain diverse volunteers for a growing number of studies in Alzheimers and related dementias. NIA convened stakeholders to develop a National Recruitment Strategy featuring goals and approaches for increasing and diversifying research participants in Alzheimers and related dementias research. Developed with the Alzheimers Association and other stakeholders, the National Strategy focuses on four overarching themes: increasing awareness and engagement nationally; building and improving capacity and infrastructure at study sites; engaging local communities and support participants; and developing an applied science of recruitment.

NIA's new Clinical Research Operations and Management System (CROMS) provides the capability to track, report, and manage NIA grantee clinical research data including participant enrollment in supported studies and other scientific portfolio activities in real time. The CROMS resource is enabling NIA and its funded investigators to intervene early to assist with enrollment challenges and support recruitment and retention of underrepresented populations in Alzheimers and related dementias research.

Outreach Pro is a new online research tool to help increase participation by traditionally underrepresented populations in clinical trials and studies on Alzheimers and related dementias. Unveiled at the Alzheimer's Association International Conference (AAIC) in July 2021, Outreach Pro enables those involved with leading clinical research to create and customize participant recruitment communications such as websites, handouts, videos, and social media posts. It is an integral part of NIAs efforts to implement the National Strategy for Recruitment and Participation in Alzheimers and Related Dementias Clinical Research.

NIAs Alzheimer's & Dementia Outreach, Recruitment & Engagement (ADORE) repository is a searchable collection of resources on topics related to the engagement, recruitment, and retention of diverse participants in dementia clinical trials and studies. Researchers, community advocates, and study coordinators can search the ADORE database to find materials and strategies to help recruit participants.

A core component of NIAs mission is to disseminate aging-related information and research advances to diverse audiences including the public, policymakers, advocates, health care professionals, the scientific community, and the media. NIAs website, social media, email alerts, print, video, and other communications channels provide evidence-based information on aging health topics and research, grants and funding, training and career development, and clinical trials.

NIAs weekly blog for researchers provides updates on NIA funding policies and research priorities, including training opportunities and health disparities research priorities. Read blogs about diversity-related issues.

NIA also develops materials for special audiences and diverse populations, including non-English language materials and materials for those with limited literacy. NIAs Spanish-language website offers evidence-based health information to Spanish speaking audiences.

NIA strongly supports UNITE, NIHs initiative to end structural racism and racial inequities in biomedical and behavioral research. A collaborative, NIH-wide effort, UNITE is designed to establish an equitable and civil culture within the biomedical research enterprise and to reduce barriers to racial equity in the biomedical research workforce.

Read NIA Director Dr. Richard J. Hodess UNITE announcement and the NIA Office of Special Populations Director Dr. Patricia Joness blog post about the initiative and related funding opportunities.

NIA participates in the NIH Community Engagement Alliance (CEAL) Against COVID-19 Disparities initiative. The goal is to build long-lasting partnerships in communities hardest-hit by COVID-19, as well as to improve diversity and inclusion in our research response to this pandemic.

The Rapid Acceleration of Diagnostics (RADxSM) initiative is a national call for scientists and organizations to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. NIA co-led the Rapid Diagnostic Accelerator for Underrepresented Populations (RADxUP) funding opportunity announcements, which are focused on COVID-19 vulnerable populations, with our partners at the NIH National Institute of Minority Health and Health Disparities and other NIH institutes, centers, and offices. NIA also co-led NIH efforts to strengthen data collection on COVID-19 to rapidly assess the needs and impact of COVID-19 across different population groups, particularly vulnerable populations. Learn more about NIA's support of the RADxSM initiative.

NIA has played a leadership role in guiding NIH Inclusion Across the Lifespan policy and convening biannual workshops to support updating and implementing this policy in clinical research. The policy mandates that diverse participants of all ages be included in human research, particularly children, older adults, and underrepresented/underserved populations, unless there is a scientific or ethical reason for exclusion of any age category. These groups have specific and unique health issues that must be examined as we study new interventions that ultimately inform health care.

NIA also participates in the NIH Diversity Catalysts program, which is led by the NIH Office of Scientific Workforce Diversity. The goal is to implement and evaluate evidence-based diversity and inclusion strategies across the NIH.

NIA supports the NIH Women of Color Research Network (WOCRN), an online community working to address issues faced by women and minorities in scientific careers. WOCRN offers links to current events, resources, and valuable connections.

Learn more about how NIH promotes a scientific workforce and the NIH offices working on scientific workforce diversity issues.

Scientific Workforce Diversity and Health Disparities Research Programs - National Institute on Aging

BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid…

Posted: at 1:49 am

PALO ALTO, Calif. & SHANGHAI & PRINCETON, N.J.--(BUSINESS WIRE)--LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, and BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced the first patient has been treated in a Phase 2a clinical trial of infigratinib in patients with locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with fibroblast growth factor receptor-2 (FGFR2) gene amplification and other advanced solid tumors with FGFR genomic alterations.

Infigratinib is a potent and selective FGFR inhibitor that has demonstrated compelling clinical activity across multiple tumor types with FGFR alterations, said Yizhe Wang, Ph.D., chief executive officer of LianBio. Given the disproportionately high prevalence rate of gastric cancer in China, LianBio is pursuing a region-specific development strategy focused on this area of great unmet need. This study marks LianBios first trial initiation and demonstrates our continued progress in delivering potentially transformational medicines to patients in Asia.

TRUSELTIQ (infigratinib) is an oral selective inhibitor of FGFR1-3 that is approved in the United States for the treatment of patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement as detected by an FDA-approved test. It is also being further evaluated in clinical trials based on demonstration of clinical activity in patients with advanced urothelial carcinoma with FGFR3 genomic alterations. LianBio in-licensed rights from BridgeBio for infigratinib for development and commercialization in Mainland China, Hong Kong and Macau.

The Phase 2a trial is a multicenter, open-label, single-arm study in China designed to evaluate the safety and efficacy of infigratinib in patients with locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with FGFR2 gene amplification and other advanced solid tumors with FGFR alterations. The primary endpoint is objective response rate (ORR). Secondary endpoints include duration of response, safety, disease control rate, progression-free survival and overall survival.

Preclinical data have demonstrated the potential infigratinib may have for patients with gastric cancer. These results, published in Cancer Discovery, demonstrated tumor regression in multiple in vivo FGFR2 amplified gastric models.1

We believe that infigratinib could have a meaningful impact for people living with gastric cancer as well as many other cancers with FGFR alterations, and are pleased LianBio is initiating this clinical trial in China where more therapeutic options are needed to match the growing diagnosis rate, said BridgeBio founder and chief executive officer Neil Kumar, Ph.D. On the heels of TRUSELTIQ recently obtaining accelerated approval in the United States, we are hopeful that this trial will yield pivotal results in another subset of cancer patients as we continue to build our portfolio of oncology indications with the aim of reaching as many people in need as possible.

About TRUSELTIQ (infigratinib)

TRUSELTIQ (infigratinib) is an orally administered, ATP-competitive, tyrosine kinase inhibitor of fibroblast growth factor receptor (FGFR) that received accelerated approval from the FDA in the United States for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. TRUSELTIQ targets the FGFR protein, blocking downstream activity. In clinical studies, TRUSELTIQ demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response. TRUSELTIQ is not FDA-approved for any other indication in the United States and is not approved for use by any other health authority, including any Chinese or other Asian health authority. It is currently being evaluated in clinical studies for first-line cholangiocarcinoma, urothelial carcinoma (bladder cancer), locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma, and other advanced solid tumors with FGFR genomic alterations.

About BridgeBio Pharma, Inc.

BridgeBio is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBios pipeline of over 30 development programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the companys first two approved therapies. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com.

About LianBio

LianBios mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and other major Asian markets, through partnerships that provide access to innovative therapeutic discoveries with a strong scientific basis and compelling clinical data. LianBio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a broad and clinically validated pipeline with the potential to impact patients with unmet medical needs. For more information, please visit http://www.lianbio.com.

About the LianBio and BridgeBio Pharma, Inc. Strategic Alliance

In August 2020, LianBio entered into a strategic alliance with BridgeBio, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers with clear genetic drivers, to develop and commercialize BridgeBios programs in China and other major Asian markets. This strategic relationship initially focuses on two of BridgeBios targeted oncology drug candidates: FGFR inhibitor infigratinib, for the treatment of FGFR-driven tumors, and SHP2 inhibitor BBP-398, in development for tumors driven by MAPK pathway mutations. The agreement also provides LianBio with preferential future access in China and certain other major Asian markets to more than 20 drug development candidates currently owned or controlled by BridgeBio. This collaboration is designed to advance and accelerate BridgeBios programs in China and other major Asian markets, allowing BridgeBio and LianBio to potentially bring innovation to large numbers of patients with high unmet need.

BridgeBio Pharma, Inc. Forward-Looking Statements

This press release contains forward-looking statements. Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as anticipates, believes, estimates, expects, intends, may, plans, projects, seeks, should, will, and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act, and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements relating to: the timing and success of the Phase 2a clinical trial of infigratinib in patients with locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with fibroblast growth factor receptor-2 (FGFR2) gene amplification, and other advanced solid tumors with FGFR genomic alterations; the planned approval of infigratinib by foreign regulatory authorities in China and the necessary clinical trial results, and timing and completion of regulatory submissions related thereto; and the competitive environment and clinical and therapeutic potential of infigratinib; reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation: the safety, tolerability and efficacy profile of infigratinib observed to date may change adversely in ex-U.S. clinical trials, ongoing analyses of trial data or subsequent to commercialization; foreign regulatory agencies may not agree with our regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; the continuing success of the BridgeBio and LianBio strategic alliance; and potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; as well as those set forth in the Risk Factors section of BridgeBio Pharma, Inc.s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent SEC filings, which are available on the SECs website at http://www.sec.gov. Except as required by law, each of BridgeBio and QED disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. Moreover, BridgeBio and QED operate in a very competitive environment in which new risks emerge from time to time. These forward-looking statements are based on each of BridgeBios and QEDs current expectations, and speak only as of the date hereof.

1 Guagnano, V., Kauffman, A., Wrle, S., et al. FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor. Cancer Discovery 2 (2012): 1118-1133.

Read more:
BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid...

Denali Therapeutics Announces Publication in Cell on New – GlobeNewswire

Posted: at 1:49 am

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced publication of preclinical proof of concept for using its Protein Transport Vehicle (PTV) to enhance brain uptake of peripherally administered progranulin (PTV:PGRN). This approach may have utility in treating certain types of frontotemporal dementia (FTD), especially FTD-GRN caused by progranulin deficiency.

Published online Thursday, August 26th, ahead of print in the September 2nd issue of Cell, the preclinical research showed that progranulin replacement therapy with Denalis PTV:PGRN rescued both neurodegeneration and microglial dysfunction in progranulin-deficient mice. The research also provides new insight into the molecular and cellular mechanisms that may contribute to FTD, identifying novel roles of progranulin in lysosomal function and lipid metabolism, as well as lysosome biomarkers with potential clinical utility.

This preclinical research demonstrates that our Protein Transport Vehicle can enhance the uptake of peripherally administered progranulin by multiple cell types in the brain, including neurons and microglia, said Denalis Chief Scientific Officer Joseph Lewcock, Ph.D. In addition, the improved mechanistic understanding of progranulins role in lysosomal function indicates that our therapeutic strategy with PTV:PGRN may be the most direct and effective way to increase progranulin levels in lysosomes for the potential treatment of people with FTD-GRN.

PTV:PGRN is engineered to bind transferrin receptor molecules, which are present in large amounts on endothelial cells of the BBB and normally function to transport iron into the brain. This approach enables PTV:PGRN to be actively transported into the brain, potentially overcoming a long-standing challenge to the field of delivering protein therapeutics across the BBB.

New insights on the role of progranulin and effects of PTV:PGRN in preclinical models of FTD

Mutations in theGRNgene, which encodes the progranulin protein,generally result in reduced protein levels of progranulin and are amongst the most common genetic causes of FTD. The studies published in Cell used two common models of FTD-GRN, genetically engineered progranulin-deficient mice as well as iPSC-derived human microglial cells, to investigate the role of progranulin and effects of PTV:PGRN treatment on disease pathology.

The preclinical research showed that lysosomes which function as the digestive system of cells are the primary cellular organelles impacted by progranulin deficiency. A new finding revealed in the preclinical studies was that progranulin regulates lysosomal function through binding to and stabilizing a lysosome-specific lipid, bis(monoacylglycero)phosphate (BMP), which is critical for normal lysosomal function.

In the progranulin-deficient mice, BMP lipid levels were profoundly decreased, which resulted in reduced activity of the lipid-metabolizing enzyme glucocerebrosidase (GCase) and accumulation of the GCase substrate glucosylsphingosine (GlcSph); GCase is known to be involved in Gaucher disease and GBA-linked Parkinsons disease. A mild decrease in BMP and an increase in GlcSph was also found in biofluid samples from patients with FTD, with or without GRN mutations.

Treatment of progranulin-deficient mice or human cells with PTV:PGRN was sufficient to rescue a range of lysosomal defects, including BMP deficiency, GlcSph accumulation, lysosomal vacuolization and lysosomal membrane damage. In addition, PTV:PGRN corrected lipofuscinosis, microgliosis and astrogliosis, which are common disease-relevant brain pathologies in progranulin-deficient mice that are also present in patients with FTD-GRN.

Collectively, these new insights from our preclinical research suggest that FTD-GRN may be an atypical lysosomal storage disorder, and that lysosomal function can be restored by PTV:PGRN, said Dr. Lewcock. Our work also identified candidate clinical biomarkers indicative of lysosomal dysfunction, such as BMP and GlcSph, which may help to evaluate the future therapeutic efficacy of PTV:PGRN and other therapeutics in people with FTD-GRN.

Publication of this research in Cell marks a significant milestone in the development of therapeutics enabled by our Transport Vehicle technology, said Denalis Chief Executive Officer Ryan Watts, Ph.D. We are making great progress towards our goal of initiating clinical testing of our lead PTV:PGRN molecule (DNL593) and believe that our unique brain-penetrant progranulin replacement approach has the potential to make a difference for individuals and their families affected by FTD-GRN.

About Denalis TV Platform

The BBB is essential in maintaining the brains microenvironment and protecting it from harmful substances and pathogens circulating in the bloodstream. Historically, the BBB has posed significant challenges to drug development for CNS diseases by preventing most drugs from reaching the brain in therapeutically relevant concentrations. Denalis Transport Vehicle (TV) platform is a proprietary technology designed to effectively deliver large therapeutic molecules such as antibodies, enzymes, proteins, and oligonucleotides across the BBB after intravenous administration. The TV technology is based on engineered Fc fragments that bind to specific natural transport receptors, such as transferrin receptor, which are expressed at the BBB and deliver TV and its therapeutic cargo to the brain through receptor-mediated transcytosis. In animal models, antibodies and enzymes engineered to the TV technology demonstrate more than 10- to 30-fold greater brain exposure than similar antibodies and enzymes without this technology. Improved exposure and broad distribution in the brain may increase therapeutic efficacy by enabling widespread achievement of therapeutically relevant concentrations of product candidates.

About Denali Therapeutics

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco. For additional information, please visit http://www.denalitherapeutics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding Denali's plans, timelines and expectations related to PTV:PGRN, plans regarding planned future clinical studies of PTV:PGRN (DNL593), expectations regarding Denalis TV technology platform, the therapeutic potential of PTV:PGRN (DNL593) and Denalis TV platform, and statements made by Denalis Chief Scientific Officer and Chief Executive Officer. Actual results are subject to risks and uncertainties and may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to, risks related to: Denalis early stages of clinical drug development; Denalis and its partners ability to complete the development and, if approved, commercialization of PTV:PGRN (DNL593); Denalis and its partners ability to enroll patients in its ongoing and future clinical trials; Denalis reliance on third parties for the manufacture and supply of its product candidates for clinical trials; the potential for clinical trial results of PTV:PGRN (DNL593) to differ from preclinical or expected results, the risk that results from early preclinical biomarker studies will not translate to clinical benefit in clinical studies; and that PTV:PGRN (DNL593) may not receive regulatory approval as a treatment of FTD-GRN necessary to be commercialized. In light of these risks, uncertainties and assumptions, the forward-looking statements in this press release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Information regarding additional risks and uncertainties may be found in Denalis Annual and Quarterly Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission (SEC) on February 26, 2021, and August 4, 2021, respectively, and Denalis future reports to be filed with the SEC. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results or to make changes in Denalis expectations, except as required by law.

Investor Relations Contact:Laura Hansen, Ph.D.Vice President, Investor Relations(650) 452-2747hansen@dnli.com

Media Contacts:Lizzie Hyland(646) 495-2706Lizzie.Hyland@FGH.comorMorgan Warners(202) 295-0124Morgan.Warners@FGH.com

See the rest here:
Denali Therapeutics Announces Publication in Cell on New - GlobeNewswire

Study tests two drug treatments for early-onset Alzheimer’s disease – National Institute on Aging

Posted: at 1:48 am

Treatment with either gantenerumab or solanezumab, two monoclonal antibodies, did not slow down cognitive decline in people who have a type of early-onset dementia called dominantly inherited Alzheimers disease (DIAD), according to a recent study. However, gantenerumab did reduce some biomarkers of the disease. The study, which was funded in part by NIA, was published in Nature Medicine on June 21.

DIAD is a rare form of Alzheimers disease. It is an inherited condition caused by mutations in certain genes. People who have DIAD often start having symptoms of dementia, such as confusion and problems with memory, reasoning, and judgment, between the ages of 30 and 50. Currently, there is no treatment to prevent or slow down the disease. In the study, researchers led by a team at Washington University School of Medicine in St. Louis tested whether gantenerumab or solanezumab can effectively treat this condition. This study was conducted as part of the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU).

The researchers enrolled participants who had gene mutations that cause DIAD. Some participants had mild symptoms of dementia, while others had no symptoms. Of the 144 participants enrolled in the clinical trial, 52 received gantenerumab, 52 received solanezumab, and 40 received a placebo. Participants were followed for up to seven years. Gantenerumab and solanezumab are monoclonal antibodies that target two different forms of a protein called beta-amyloid. In people with Alzheimers disease, beta-amyloid clumps together to form plaques in the brain. This prevents brain cells from working properly.

The researchers found that in participants who had symptoms of dementia at the beginning of the trial, treatment with gantenerumab or solanezumab did not slow down or stop the worsening of these symptoms. Some participants taking solanezumab had a faster cognitive decline. Participants who had no symptoms at the start of the study did not develop symptoms during the study.

The researchers also tested whether either of the two drugs had an effect on known biomarkers of Alzheimers. Both drugs effectively hit their amyloid-beta targets. Gantenerumab reduced beta-amyloid plaques in the brain and lowered the levels of tau, a protein that forms tangles in the brain cells of people who have Alzheimers. Additionally, gantenerumab slowed down the accumulation of a protein called neurofilament light chain (NfL). High NfL levels are a sign of increased brain cell damage. Solanezumab showed effects on cerebral spinal fluid amyloid-beta but had no effect on beta-amyloid plaques. Tau levels were also not affected and NfL levels increased.

The researchers note that although this study was limited by a small sample size and a relatively short monitoring period, it presents an effective model for studying potential treatments for DIAD. In future DIAN-TU studies, the researchers plan to classify participants into smaller groups based on their disease stages for more accurate comparisons between participants who received treatments and the control group. They also plan to test higher doses of study drugs for longer periods to fully examine their efficacy in treating DIAD.

This research was supported in part by NIA grants AG042791, AG042791-S1, AG046179, AG053267-S1, and AG032438.

These activities relate to NIHs AD+ADRD Research Implementation Milestone 5.C, Initiate phase III drug trials for agents against at least 3 currently known therapeutic targets. Of these, at least one trial will be asymptomatic, at risk populations; and 10.C, Initiate 3-4 clinical research studies using common standard outcome measures.

Reference: Salloway S, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimers disease. Nature Medicine. 2021. Epub Jun 21. doi: 10.1038/s41591-021-01369-8.

Read the original here:
Study tests two drug treatments for early-onset Alzheimer's disease - National Institute on Aging

Berries might be able to slow the onset of Alzheimer’s disease – hortidaily.com

Posted: at 1:48 am

Americans are growing old and, sadly, the aging process for many means more than simply turning gray or thinning hair.

According to theUnited States Census, in about a dozen years the number of Americans over 65 will outnumber children. Further, the Centers for Disease Control and Prevention project the number of Americans living with Alzheimers disease (AD) to nearlytriple by 2060.

Berries might help slow the processFortunately, USDA-funded research may have found a tasty way to slow disease onset.Astudypublished in theAmerican Journal of Clinical Nutritionsuggests that diets high in flavonoids may protect cognitive health. Flavonoids are plant nutrients known for their antioxidant, antiviral, and anticancer properties and are found in berries, tea, dark chocolate, and other foods.

Alzheimers disease is a significant public health challenge, saidPaul Jacques,nutritional epidemiologistat theJean Mayer USDA Human Nutrition Research Center on Agingat Tufts University in Boston. Given the absence of drug treatments, preventing Alzheimers disease through a healthy diet is an important consideration.

Photo credits: Scott Bauer, K7229-19

According to Jacques, who co-authored the study, about one in nine adults over age 65 are living with AD. While memory loss is the hallmark of AD, Jacques said it has many other cognitive and behavioral changes, including difficulty carrying out simple multistep activities, such as dressing or cooking; loss of judgement and attention; and changes in behavior such as depression and agitation.

Promising flavonoidsJacquess study, one of the first truly large, long-term studies to examine the effects of flavonoids on AD, showed that diets high in certain types of flavonoids present significant promise toward preventing the onset of Alzheimers.

Our study examined the association between long-term flavonoid intakes and AD over an average follow-up of 19.6 years among 2,809 participants, he said. Results show that those who consumed the most flavonoids were more than 50 percent less likely to develop AD risks compared with those who ate the least. Plant foods, such as vegetables, fruits, berries, nuts, and seeds are good sources of flavonoids, as is a cup of green tea each day.

Age 50 is not too late to make positive dietary changes. While the risk of dementia increases over age 70, it is now believed that its preclinical stage may predate clinical diagnosis by decades he said. A healthy diet during this preclinical period may provide the best opportunity for slowing the development of AD. When you approach 50, you should start thinking about a healthier diet if you havent already.

According to Jacques, flavonoid-rich diets help more than just Alzheimers disease and related dementia.

The bottom line is that there are many reasons to consume a healthy diet, including lower risks of cardiovascular disease and some cancers. We can now add protection of cognitive health and prevention of Alzheimers disease to that list," said Scott Elliott, ARS Office of Communications

Visit link:
Berries might be able to slow the onset of Alzheimer's disease - hortidaily.com

Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimers Disease Summit – Yahoo Finance

Posted: at 1:48 am

Presentation to highlight the potential of early clinical assessment of biomarkers to drive development of Alzheimers disease therapies

CAMBRIDGE, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced participation in the Annual Biomarkers for Alzheimers Disease Summit taking place virtually August 25-26, 2021. Chris Winrow, Ph.D., Head of Translational Medicine, will present on biomarker translation and the potential that early clinical assessment of biomarkers has to drive development of Alzheimers disease therapies, and Juli Jones, Ph.D., Head of Disease Biology, will be leading a session exploring the utilization of omics platforms in drug discovery.

Presentation Details:

Title: Exploring the Utilization of Omics Platforms in Drug DiscoveryModerator: Juli Jones Ph.D., Head of Disease Biology, Cyclerion Therapeutics, Inc.Date: Wednesday, August 25, 2021Time: 4:20 p.m. ET

Title: Leading the Vanguard Early Clinical Assessment of Biomarkers to Drive Development of Alzheimers Disease TherapiesPresenter: Chris Winrow, Ph.D., Head of Translational Medicine, Cyclerion Therapeutics, Inc.Date: Thursday, August 26, 2021Time: 2:30 p.m. ET followed by a live Q&A at 3:00 p.m. ET

About Cyclerion Therapeutics

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion is advancing novel, first-in-class, CNS-penetrant, sGC stimulators that modulate a key node in a fundamental CNS signaling pathway. The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases. The most advanced compound, CY6463, has shown rapid improvement in biomarkers associated with cognitive function and is currently in clinical development for Alzheimer's Disease with Vascular pathology (ADv), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS), and Cognitive Impairment Associated with Schizophrenia (CIAS). Cyclerion is also advancing CY3018, a next-generation sGC stimulator.

Story continues

For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).

InvestorsCarlo Tanzi, Ph.D.Kendall Investor Relationsctanzi@kendallir.com

MediaAmanda SellersVerge Scientific Communicationsasellers@vergescientific.com

Continue reading here:
Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimers Disease Summit - Yahoo Finance

Longevity resources: Reaching the Latino community and vice versa – Aspen Times

Posted: at 1:47 am

Estrella Portillo knows seeking immediate mental health assistance in relation to the Latino community is a big challenge.

Portillo, a 28-year-old Latina who moved to the Roaring Fork Valley from Mexico when she was 12, encountered these challenges almost immediately.

I have struggled with depression and anxiety for a long time, she said. Though she realized and understood what these mental symptoms were, there was a seemingly impenetrable stigma attached to them. Because in my family, if you have accepted that you have a mental illness, then youre weak.

The Glenwood Springs High School graduate said from adults to children, Latinos are reluctant to get the proper care and resources they need for any type of mental health issues, including substance abuse and suicide.

Im coming from a family of immigrants, and mental health is just nonexistent, she said. Its something thats not talked about in Latino families. We just brushed it under the rug.

Portillo takes classes through Naropa University in Boulder, and has recently been researching ways to foster more mental health awareness among the Hispanic community of the Roaring Fork Valley. Her research has so far uncovered barriers such as neglect, access to health insurance and language leading to significant mental health challenges.

They come here to work and have a better life for their families or themselves, and theyre running away from something major, whether it was a traumatic experience, violence, poverty, she said. And all they do here is work. They dont know how to give themselves the space and time to work on themselves emotionally.

They dont feel like they have someone that they trust, she added.

For some, theres also a language barrier.

I definitely think theres a need for more bilingual professionals, Portillo said. And everywhere, from cops to nurses to therapists to social workers and just people that are spreading awareness its not enough.

Leslie Venegas is trying to alleviate this dilemma. The bilingual Latina runs the Celebrate Recovery program in New Castle and is a peer specialist at Mind Springs Health in Glenwood Springs.

I see a lot of need from the Hispanic community, so Ive encountered a lot of people that are in need of resources, she said. Either theyre not informed, or there are not many resources available to them.

Venegas said there are simply more resources available to the English-speaking community.

And theres a lot of Hispanics that dont speak English, or they dont feel comfortable coming to somebody that doesnt come from the same background as them, because we are a different culture, she said.

Celebrate Recovery is a Christian-based, 12-step recovery program designed to help anyone struggling with hurt, pain or addiction of any kind, according to its mission stated online. Mind Springs Health, meanwhile, is Western Colorados largest provider of counseling and therapy for mental wellness.

Like Aspen Strong, Celebrate Recovery provides a 24/7 call-in service for people requesting immediate assistance, as well as additional treatment options. And with people like Venegas on the frontlines, it helps better reach the Latino community.

I pretty much meet with people that are struggling with substance use disorder, or mental health, Venegas said. Its kind of a support system to help them connect them to different people or support systems.

Were a really good resource for people, because weve been there, she added.

Reporter Ray K. Erku can be reached at 612-423-5273 or rerku@postindependent.com.

Go here to see the original:
Longevity resources: Reaching the Latino community and vice versa - Aspen Times

Steph Curry looks to Tom Brady for inspiration in pursuit of NBA longevity – USA TODAY

Posted: at 1:47 am

NFC South preview: Can anyone beat Tom Brady and the Buccaneers?

SportsPulse: USA TODAY Sports' Mackenzie Salmon breaks down the expectations for each team in the NFC South this season.


Stephen Curry wants to play basketball as long as the game still brings him joy, according to NBC Sports Monte Poole. Hes about to enter his 13th season in the NBA, all of them with Golden State after the Warriors picked the 6-foot-3 guard seventh overall in 2009.

When looking for longevity in sports, Curry knows there is no better player to study than Tom Brady.

Absolutely. Ive actually talked to him, personally, about this, Curry told NBC Sports Bay Area. Hes at the point now where he can look back and talk about that with some authority and experience.

But even he said, in the moment, when he was in his early-30s, mid-30s, late-30s, it was always, I think Ive still got two more years in me. Stay. Do everything I can to sustain yourself and stay physically and mentally sharp. And then you look up and youre saying that again, saying it in the next two years. And youre saying it again.

The 44-year-old quarterback for the Tampa Bay Buccaneers is set play in his 22nd NFL season. Hes led his teams the Bucs and the New England Patriots to 10 Super Bowl appearances and seven victories, including his most recent one this year, where he was named MVP with the Bucs.

Brady has cemented his spot in football history. He needs six more seasons to dethrone George Blanda as the NFL player with the most career seasons.

Ill know when the times right, Brady said to NBC Sports. If I cant…if Im not a championship-level quarterback, then Im not going to play. If Im a liability to the team, I mean, now way. But if I think I can win a championship, then Ill play.

Curry is looking to duplicate Bradys success, only in basketball. Earlier this month, he signed a historic four-year, $215 million extension, making him the first NBA player ever to have signed two $200 million-plus contracts. He's set to remain with the only team hes ever known through 2026.

Its dope to think about what has all transpired in the last 12 years, Curry told The Athletic about signing a new deal. Thinking about being in the Bay for another five years, taking me to 38, it checks all the boxes in terms of what Im trying to do with my career.

Last season, he was named back-to-back Player of the Month for the first time in his career. Curry already has three championship rings, leading the Warriors to wins in 2015, 2017 and 2018. On top of that, hes a seven-time All-NBA, two-time NBA MVP and won the NBA Sportsmanship Award.

Curry will look to add more to that resume, but for now, hes not thinking about retirement or whats down the road, according to NBC Sports.

Its all about staying in the moment, and not fast-forwarding, putting too much pressure on yourself to reach that milestone, he said. You do everything now to set yourself up for now and the future. Staying in the moments is all a part of getting there. So, the vision is there. But Im looking forward to the next 12 months.

Contact Alyssa Hertel at ahertel@usatoday.com or on Twitter @AlyssaHertel.

View original post here:
Steph Curry looks to Tom Brady for inspiration in pursuit of NBA longevity - USA TODAY

This tech investor believes well soon live to 150. Here are his seven longevity hacks – The Irish Times

Posted: at 1:47 am

The possibility of living 150 or even 200 years is within humanitys grasp and advances in diagnostics, treatments and organ regeneration and replacement are moving this prospect ever nearer. Early death from diseases such as cancer, heart disease and diabetes will no longer be inevitable for millions of people.

These are among the tantalising and radical ideas Sergey Young presents in his book The Science and Technology of Growing Young (published by BenBella Books).

Slowing, reversing or even ending ageing will become a universally accepted ambition in the healthcare community, he says. Technology is converging to make this a certainty. Developments in the understanding and manipulation of our genes and cells, in the development of small-scale health diagnostics and in the leveraging of data for everything from drug discovery to precision treatment of disease are radically changing how we think about healthcare and ageing, he says.

With a background in fund management and investing, Youngs own epiphany came when doctors told him that he would need to take statins for the rest of his life to control his high cholesterol. This has led him into researching the science of ageing and the frontiers of medicine and technology. His $100 million Longevity Vision Fund invests in companies at the edge of breakthroughs in life-extension technology and he is a board member of the American Federation of Aging Research.

Young insists that he is not in the business of trying to cheat death personally. Even if I die at the age of 80, which would be typical for my cohort, I want to have done so sharing the best ideas about longevity. If that benefits my children and grandchildren and society in general thats a good legacy.

With a regular regime of intensive health checks, body sensors and a rigorous diet and exercise regime, Young practises what he has learned on his journey around the bleeding edge of medical research and clearly intends maximising his own lifespan.

Though he is not a doctor, Youngs extensive research among the medical and life science community synthesised much of the best thinking on arresting ageing. His book provides a fascinating look at whats possible within both near and longer-term horizons, ranging over subjects such as gene editing, stem cell therapy, organ replacement and bionic augmentation.

If we want to life a long life, the best thing we can do right now, he says, is to be proactive about our health so we can stick around for the medical and technological advances that are coming down the tracks in next decade or so that could prevent or cure what he calls the monster diseases, such as cancer and heart disease.

That seems like an audacious claim. But take cancer, for example. Eighty years ago, there was no drug to treat it but now there are at least seven pharmaceutical approaches to cancer treatment and more than 100 chemotherapy drugs in use. Five-year survival rates from cancer have been improving by close to 2 per cent a year for the past 50 years. That rate of progress is set to explode in the years ahead, he says.

Cancer medicine right now is largely reactive, and treatment often starts too late. Young envisages a future with low-cost ubiquitous connected devices that will constantly monitor your health. Some will be external while others will be embedded under your skin. Some could be swallowed with your breakfast or remain swimming through your bloodstream at all times, monitoring your heart rate, respiration, skin secretions and free-floating DNA in your body that may indicate cancer or other diseases.

Early detection of diseases will be complemented by vastly improved drugs and treatments aided by artificial intelligence. Consider how quickly and effectively vaccines have been developed and deployed in the Covid-19 pandemic, he notes.

Then consider the issue of organ and limb replacement and regeneration. Advances in areas such as 3D printing and life science mean that a whole host of damaged or diseased body parts can be replaced. We can have new organs, grown in many cases by our own cells, mitigating the prospect that our bodies will reject them.

Add all this science and technology progress together and the prospect of breaching the current limit of human life of about 120 years, is not only feasible, but inevitable, he believes. Not alone would we live longer but we would enjoy the benefits of living healthier lives for longer too.

For many, this utopian vision raises disturbing questions. There are a whole host of moral and ethical issues here. Would the benefits of defying ageing be spread evenly across social classes and geographies? Do people really want to live a lot longer? Could the planet contain the increase the population? Would a new divide emerge between the body enhanced older population and traditionalists resistant to this form of progress?

Young responds by saying that doing nothing would be truly immoral. Existing healthcare costs are enormous, he points out. Technology offers a pathway to cheaper ubiquitous healthcare solutions that are within the grasp of everyone. Fertility rates are declining in many parts of the globe and advances in technology will result in greater sustainability in energy and food production.

A longevity revolution is on the way but it is disruptive innovators rather than Big Pharma who will lead the way, he believes. The medical establishment will ultimately embrace it as doctors are swamped with patients and outmoded treatments. Access to the best information, drugs and technology will empower doctors to provide better, more affordable and empathetic care to their patients and expensive hospital admissions could plummet.

In as little as 10 years we will look back at the treatment of ageing and disease as quite naive, Young concludes.

No smoking and restrict alcohol: Smoking is the biggest no-no for longevity for obvious reasons. High and regular use of alcohol damages your liver and pancreas, causes high blood pressure, increases your risk of stroke, brings on immune system disorders, leads to early onset Alzheimers disease and contributes to at least 200 more health conditions.

Slash sugar consumption: Excess sugar is poison, he says. It wears out the pancreas among other problems. Eliminate it wherever possible. Cut out all processed foods and limit fructose. Restrict carbs as they ultimately break down into glucose.

Fasting: Calorie reduction reduces the chances of developing health problems such as diabetes, cancer, heart disease and cognitive decline and preserves immune system function. Young recommends an intermittent fasting regime where you eat all of your meals within an eight-hour period early in the day and then refrain from eating until the next morning. Clinical data shows that intermittent fasting can improve weight loss, insulin stability, cholesterol levels.

Food as medicine: Stick to an organic, mainly plant-based diet, eliminating processed foods. Choose grass-fed free-range meat and wild caught fish. Include health fats such as extra virgin olive oil which has high anti-oxidant anti-inflammatory and anti-allergic properties that can help preserve cell condition and protect from a range of diseases. He also recommends the use of supplements to provide the nutrients we cant get from our foods.

Consume more water: Regular consumption of water improves resting calorie burn by up to 30 per cent and encourages you to consume less sugary and caffeine drinks. It also suppresses hunger so you will eat less.

Sleep more: Sleep deprivation significantly increases your chances of a heart attack. The link between poor sleep and cancer is so strong that the International Agency for Research on Cancer (IARC) has classified night-shift work as a probable carcinogen. Young says we should use every trick in the book to aid sleep including transitions rituals such as hot baths, cool bedrooms, black-out curtains, meditation and ditching digital devices at night.

Exercise: Even moderate exercise can add up to seven years to our lives, can cut cancer rates by up to 23 per cent and maintain cardio health among other benefits. Walking is a great start. Try to do 10,000 steps a day.

This tech investor believes well soon live to 150. Here are his seven longevity hacks - The Irish Times

« Previous Post  Next Posts »

Page 3«..2345..10..»